cagrisema semaglutide cagrilintide phase 3 results 2025 Presenters to provide first look at data from REIMAGINE trials of cagrilintide/semaglutide for type 2 diabetes management Novo Nordisk's next-gen obesity drug
Novo Nordisk's next gen obesity drug CagriSema trial results disappoint investors 1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or cagrisema phase 3 results 2025 semaglutide cagrilintide obesity REDEFINE 1 Trial CagriSema Outperforms Semaglutide Alone Across Novo's Phase 3 CagriSema results disappoint analysts, sending stock tumbling MM+M Medical Marketing and Media CagriSema in Adults With or Without Diabetes REDEFINE 1 & 2 Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly 20.4% weight loss (non diabetic) & 13.7% (T2D) Novo Nordisk's stock drops despite CagriSema hitting goal of Phase III trial Clinical Trials Arena
Pay in 4 interest-free payments of $6.22 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11




